Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more
Location: 1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States | Website: https://www.savarapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
603.2M
52 Wk Range
$1.89 - $4.29
Previous Close
$3.49
Open
$3.53
Volume
846,048
Day Range
$3.43 - $3.58
Enterprise Value
486.5M
Cash
146.9M
Avg Qtr Burn
-24.85M
Insider Ownership
5.38%
Institutional Own.
97.72%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Molgramostim Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Phase 3 Data readout |